Ronda Stryker Sells 276,173 Shares of Stryker (NYSE:SYK) Stock

Stryker Corporation (NYSE:SYK) Director Ronda Stryker sold 276,173 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Stryker Price Performance

Shares of SYK opened at $355.74 on Friday. The business’s fifty day moving average is $374.63 and its 200 day moving average is $381.22. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $136.04 billion, a P/E ratio of 47.12, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the business posted $2.87 EPS. Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent research reports. Wells Fargo & Company raised their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research note on Wednesday, October 8th. Rothschild Redb raised Stryker to a “hold” rating in a research report on Thursday, September 18th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Finally, Evercore ISI dropped their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Fourteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $433.37.

Institutional Investors Weigh In On Stryker

Several large investors have recently made changes to their positions in SYK. Fiera Capital Corp grew its position in Stryker by 24.5% during the third quarter. Fiera Capital Corp now owns 28,828 shares of the medical technology company’s stock valued at $10,657,000 after buying an additional 5,667 shares during the period. Burling Wealth Partners LLC boosted its stake in Stryker by 34.6% in the third quarter. Burling Wealth Partners LLC now owns 11,743 shares of the medical technology company’s stock valued at $4,341,000 after acquiring an additional 3,021 shares during the last quarter. King Luther Capital Management Corp grew its position in shares of Stryker by 3.2% during the 3rd quarter. King Luther Capital Management Corp now owns 461,653 shares of the medical technology company’s stock valued at $170,659,000 after acquiring an additional 14,174 shares during the period. Harold Davidson & Associates Inc. increased its stake in shares of Stryker by 41.3% during the 3rd quarter. Harold Davidson & Associates Inc. now owns 8,687 shares of the medical technology company’s stock worth $3,211,000 after purchasing an additional 2,538 shares during the last quarter. Finally, Comgest Global Investors S.A.S. raised its holdings in shares of Stryker by 16.2% in the 3rd quarter. Comgest Global Investors S.A.S. now owns 98,944 shares of the medical technology company’s stock worth $36,577,000 after purchasing an additional 13,806 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.